Erbitux Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Erbitux (cetuximab) is a monoclonal antibody used to treat cancers such as metastatic colorectal cancer and head and neck cancer by targeting the epidermal growth factor receptor (EGFR) and inhibiting tumor growth.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of erbitux include the 100 mg/50 mL injection and the 200 mg/100 mL injection. The 100 mg/50 mL injection refers to a medical formulation in which 100 milligrams (mg) of the active drug or substance is dissolved in a total volume of 50 milliliters (mL) of liquid. Erbitux products, including tablets and pills, are used for conditions such as head and neck cancer and metastatic colorectal cancer. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and other outlets.

The erbitux market research report is one of a series of new reports from The Business Research Company that provides erbitux market statistics, including erbitux industry global market size, regional shares, competitors with erbitux market share, detailed erbitux market segments, market trends and opportunities, and any further data you may need to thrive in the erbitux industry. This erbitux market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The erbitux market size is expected to see rapid growth in the next few years. It will grow to $3,068.5 million in 2029 at a compound annual growth rate (CAGR) of 18%. The growth in the forecast period can be attributed to the rising number of cancer cases globally, growing demand for the treatment of metastatic colorectal cancer, increasing awareness of the disease, increasing demand for novel therapeutics, and growing consciousness among medical practitioners. Major trends in the forecast period include advancements in personalized medicine, continuous research to improve cetuximab's efficacy, developments of biosimilars, effective marketing strategies, and innovations in drug development.

The increasing number of cancer cases worldwide is expected to drive the growth of the erbitux market. Cancer refers to a wide variety of diseases where abnormal cells grow uncontrollably and can spread to other parts of the body. The global rise in cancer cases is largely attributed to an aging population and growing lifestyle risks, including poor diet and physical inactivity. Erbitux (cetuximab) is a targeted therapy designed to treat cancers with overexpressed EGFR, such as colorectal and head and neck cancers, improving survival rates and aiding in the management of the global cancer burden. For example, the National Health Service (NHS) reported in October 2024 that in 2022, there were 346,217 new cancer diagnoses in the UK, averaging 948 cases per day, a 5% increase from 2021's 329,664 diagnoses. The rise was more significant among men, with a 7% increase in overall cancer diagnoses, from 167,917 in 2021 to 180,877 in 2022. Therefore, the increasing global incidence of cancer is driving the erbitux market.

A key trend in the erbitux market is the focus on developing innovative solutions to improve the effectiveness and affordability of cetuximab (Erbitux). Cetuximab, marketed under the brand name Erbitux, is a monoclonal antibody used primarily to treat certain cancers, including colorectal and head and neck cancers. For instance, in May 2023, Enzene Biosciences Limited, an India-based contract development and manufacturing organization, launched Cetuximab, a biosimilar of the cancer drug Erbitux, targeting metastatic colorectal and head and neck cancers. This marked the approval of the first biosimilar for cetuximab, offering a more affordable treatment option for patients. Cetuximab works by inhibiting the epidermal growth factor receptor (EGFR), which plays a key role in tumor growth and metastasis. Produced using a Chinese Hamster Ovary (CHO) cell line, Enzene's biosimilar aims to enhance treatment accessibility in India and other markets, supporting the company's strategy to expand its biosimilar portfolio.

In May 2023, Lupin Limited, an India-based pharmaceutical company, formed a partnership with Enzene Biosciences Limited. The collaboration between Lupin and Enzene Biosciences aims to launch the first biosimilar of Cetuximab for treating head and neck cancer in India. This partnership seeks to expand treatment options and improve patient access to therapies for recurrent or metastatic conditions, ultimately enhancing healthcare outcomes for patients dealing with public health challenges related to this type of cancer. Enzene Biosciences Limited is an India-based biotech company that provides Cetuximab, the first biosimilar of the cancer treatment drug Erbitux.

Major players operating in the erbitux market are Eli Lilly and Co.; Bristol Myers Squibb; Merck KGaA

North America was the largest region in the erbitux market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in erbitux report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the erbitux market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The erbitux market consists of sales of products including Vectibix, Tarceva, Iressa, and Tagrisso. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Erbitux Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on erbitux market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for erbitux ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The erbitux market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types: 100 Mg/50 ML Injection; 200 Mg/100 ML Injection
• 2) By Product: Tablet; Pill
• 3) By Applications: Head And Neck Cancer; Metastatic Colorectal Cancer
• 4) By End User: Hospital Pharmacy; Retail Pharmacies; Other End Users
• Companies Mentioned: Eli Lilly and Co.; Bristol Myers Squibb; Merck KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.